2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Computational Biology, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Gene Therapy, Non-Biological Therapies, Women’s Health, Adverse Events, Artificial Intelligence (AI), Biological Processes, Pathogenesis, Microbiome, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality of Care, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Infectious Diseases, Viral, Bacterial, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2950 Persistent anemia partially mediates increased hospitalization rates in end stage kidney disease due to sickle cell disease

Krystle Denise Frazier, MD, Charles McCulloch, PhD2, Elaine Ku, MD, MAS3
1 University of California San Francisco, San Francisco, California, United States
2 University of California San Francisco, San Francisco, California, United States
3 University of California San Francisco, San Francisco, California, United States

Background: Anemia is linked to increased mortality for individuals receiving hemodialysis (HD).  However, hemoglobin may not reach recommended targets in individuals with end stage kidney disease (ESKD) and sickle cell disease (SCD-ESKD) due to chronic hemolysis and resistance to erythropoietin stimulating agents. The objective of this retrospective study was to examine the relationship between the cause of ESKD (SCD versus polycystic kidney disease (PKD)) and the risk of hospitalization in individuals receiving HD, and to understand whether this relationship is mediated by anemia.

Exposures: Cause of ESKD (e.g. SCD or PKD)

Outcomes: All-cause hospitalization 

Methods:  Using data from the national ESKD registry, the United States Renal Data System (USRDS), the association between the cause of ESKD and hospitalization was examined using adjusted Cox proportional hazards regression models. Mediation analysis used generalized structural equation models with an accelerated failure time Weibull model to estimate the degree to which the association between cause of ESKD and all-cause hospitalization was mediated by achieved hemoglobin 3 months after HD initiation.

Results: We included 515 individuals insured by Medicare with SCD-ESKD (mean age 48 years ± 13, 48% female) and 9,756 with PKD-ESKD (mean age 60 years ±14, 45% female) who started HD between June 1, 2012 and December 31, 2021. During follow-up, participants in the PKD-ESKD group contributed 293,782 person-years and experienced 115,254 hospitalizations, corresponding to 0.39 hospitalizations per person-year. Participants in the SCD-ESKD group contributed 6,722 person-years and experienced 5,626 hospitalizations, corresponding to 0.84 hospitalizations per person-year. In an adjusted Cox proportional hazards model, individuals with SCD-ESKD had a 3.57 higher hazard (95% CI 3.18-4.01, p<0.001) of all-cause hospitalization compared to those with PKD-ESKD. The top three causes of hospitalization for the SCD-ESKD subgroup were vaso-occlusive episodes (VOE), sepsis and pneumonia. The top three causes of hospitalization for the PKD-ESKD subgroup were sepsis, pneumonia and cardiovascular events.  The SCD-ESKD subgroup had a 4.15 higher hazard (95% CI 3.55-4.85, p<0.001) for sepsis and a 5.91 higher hazard (4.93-7.1, p<0.001) for pneumonia-related hospitalizations compared to the PKD-ESKD group. The mean hemoglobin by the 3rd month of HD was 7.6 mg/dL (95% CI 7.5-7.7) for SCD-ESKD and 11.6 mg/dL (95% CI 11.6-11.7) for PKD-ESKD. In mediation analysis, approximately 31% of the association between SCD-ESKD and all-cause hospitalization was mediated through hemoglobin.

Conclusions: Persistent anemia shortly after HD initiation partially mediates the risk of all-cause hospitalization in patients with sickle cell disease receiving HD.  Achieving higher hemoglobin in this population may potentially reduce the risk of hospitalization in those with SCD-ESKD.

Krystle Denise Frazier, MD: No relevant conflicts of interest to declare.